Press coverage about Eleven Biotherapeutics (NASDAQ:EBIO) has trended positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eleven Biotherapeutics earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.4808959188188 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Eleven Biotherapeutics (NASDAQ EBIO) traded down $0.02 during trading hours on Thursday, hitting $0.65. 840,800 shares of the stock were exchanged, compared to its average volume of 460,692. Eleven Biotherapeutics has a one year low of $0.62 and a one year high of $2.56.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/30/positive-news-coverage-somewhat-unlikely-to-impact-eleven-biotherapeutics-ebio-stock-price.html.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Insider Buying and Selling by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)

Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.